With shares of International Business Machines (NYSE:IBM) trading around $173, is IBM an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementIBM is an information technology company. The company operates in five segments: Global Technology Services, Global Business Services, Software, Systems and Technology, and Global Financing. Technology products and services are in high demand worldwide as consumers want to be up-to-speed, and companies always need the latest and greatest to stay ahead of the competition. Cloud computing has been hot in recent times, which has not been good news for IBM. Should the company want to hold on to its market share, it needs to make moves quickly, and provide the technology products and services that worldwide consumers and companies demand.
An IBM executive said that the company is still facing difficulties linked to a slow economy. Speaking at a Bank of Montreal conference in New York on Tuesday, Senior Vice President Erich Clementi said that IBM will continue to see falling sales figures unless the economy turns around, according to a report from Bloomberg.�IBM�� revenue ��epends on what the economic climate is, and that has not been very encouraging,��Clementi said. ��urope has shown signs of recovery. North America has been a little more uncertain.��Clementi added that the company is focusing most of its efforts on cloud computing and software over hardware.
Hot Asian Companies To Own For 2015: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Ben Levisohn]
Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.
- [By Mani]
Pharmacyclics, Inc. (NASDAQ: PCYC) is one of the best ways to play the hematology cancer drug market as its Ibrutinib is expected to transform the treatment of many blood cancers.
- [By MONEYMORNING]
We saw this last year with such Private Briefing recommendations as The Boeing Co. (NYSE: BA) and Pharmacyclics Inc. (Nasdaq: PCYC), which rose more than 100% and 400%, respectively, following our recommendation.
- [By Maxx Chatsko]
The astounding rise of Pharmacyclics (NASDAQ: PCYC ) through the markets has been largely based on its BTK inhibitor ibrutinib, which is being evaluated in four types of blood cancers and in a preclinical study for autoimmune indications. The rise is no fluke, either. Ibrutinib has shown very promising results in two phase 2 trials as a monotherapy and will soon be moved to phase 3 trials for both. With billions of dollars between the lymphoma and autoimmune markets up for grabs, it is easy to see why shares have risen 2,000% since the company acquired its lead drug candidate in 2006. Can Celgene tap into this multibillion opportunity with CC-292? Ask me again in about five years.�
Top 5 Information Technology Companies To Own For 2014: Rockwell Automation Inc.(ROK)
Rockwell Automation, Inc. provides industrial automation power, control, and information solutions. It operates in two segments, Architecture and Software, and Control Products and Solutions. The Architecture and Software segment offers control platforms that perform multiple control disciplines and monitoring of applications, including discrete, batch and continuous process, drives control, motion control, and machine safety control; and products comprising controllers, electronic operator interface devices, electronic input/output devices, communication and networking products, and industrial computers. This segment also offers software products, such as configuration and visualization software used to operate and supervise control platforms, advanced process control software, and manufacturing execution software to enhance manufacturing productivity and meet regulatory requirements; and rotary and linear motion control products, and sensors and machine safety components . The Control Products and Solutions segment provides low and medium voltage electro-mechanical and electronic motor starters, motor and circuit protection devices, AC/DC variable frequency drives, push buttons, signaling devices, termination and protection devices, relays and timers, and condition sensors; and packaged solutions, such as configured drives and motor control centers to automation and information solutions, as well as life-cycle support services. The company sells its products, solutions, and services primarily under the Rockwell Automation, Allen-Bradley, A-B, and Rockwell Software brand names to the food and beverage, transportation, oil and gas, metals, mining, home and personal care, pulp and paper, and life sciences markets through independent distributors and direct sales force in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Rockwell Automation, Inc. was founded in 1928 and is headquartered in Milwaukee , Wisconsin.
Advisors' Opinion:- [By Rich Duprey]
Industrial automation specialist�Rockwell Automation� (NYSE: ROK ) �announced yesterday�its third-quarter dividend of $0.52 per share, the same rate it paid last quarter after raising the payout almost 11% from $0.47 per share.
- [By David Sterman]
So which companies are likely to most greatly benefit from an eventual rise in capital spending? Firms involved in construction, business process automation, and other productivity tools. Here's a short sample, though you should keep an eye out for any companies that have a high level of sensitivity to changes in capital spending levels.
1. Rockwell Automation (NYSE: ROK) This maker of factory automation systems has managed to boost sales less than 10% from fiscal 2008 to fiscal 2012. Yet management hasn't been waiting around for business to improve. In that time, Rockwell has been investing hundreds of millions in its Logix Automation control platform, an open-source software system that enables all components of a production process control system to easily interoperate. Moreover, Rockwell's core strength in manufacturing has now been extended into the fields of energy refineries, mining, and food and beverage production. - [By Rick Munarriz]
Rockwell Automation (NYSE: ROK ) isn't being an automaton with its disbursements. The leading player in industrial automation and information is jacking up its quarterly payouts 11% to $0.52 a share. This may not seem like much, but string enough of these increases along and you really move the needle. Rockwell's rate has soared 80% over the past four years.
Top 5 Information Technology Companies To Own For 2014: Powershares DB Commodity Index Tracking Fund (DBC)
PowerShares DB Commodity Index Tracking Fund (the Fund) and its subsidiary, DB Commodity Index Tracking Master Fund (the Master Fund), were formed as trusts. The Fund is designed to replicate positions in a commodity index.
The PowerShares DB Commodity Index Tracking Fund is based on the Deutsche Bank Liquid Commodity Index - Optimum Yield Excess Return (Index). The Fund is managed by DB Commodity Services LLC.
Advisors' Opinion:- [By Doug Fabian]
PowerShares DB Commodity Index Tracking Fund (DBC) is a fund that tracks a basket of commodities, including gold, silver, Brent crude oil, RBOB gasoline, heating oil, sugar, corn, soybeans, and much more.
- [By Richard Stavros]
Another futures-based ETF is PowerShares Deutsche Bank Commodity Index (DBC). It is more diversified than DBA. It holds futures contracts in corn and wheat. But it also holds significant positions in gold, heating oil, and crude.
Top 5 Information Technology Companies To Own For 2014: Signet Jewelers Limited(SIG)
Signet Jewelers Limited operates as a specialty jewelry retailer in the United States, the United Kingdom, the Republic of Ireland, and the Channel Islands. The company retails jewelry, watches, and associated services. As of January 28, 2012, it operated a network of 1,318 stores in 50 states in the United States that trade nationally in malls and off-mall locations as ?Kay Jewelers?, and regionally under various mall-based brands, as well as operated as destination superstores under the ?Jared The Galleria Of Jewelry? trade name. The company also operated a network of 535 stores in the United Kingdom, including 14 stores in the Republic of Ireland and 3 in the Channel Islands under the ?H.Samuel?, ?Ernest Jones?, and ?Leslie Davis? trade names in high street locations and shopping malls. Signet Jewelers Limited was founded in 1950 and is based in Hamilton, Bermuda.
Advisors' Opinion:- [By Seth Jayson]
Signet Jewelers (NYSE: SIG ) reported earnings on May 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended May 4 (Q1), Signet Jewelers missed estimates on revenues and beat slightly on earnings per share. - [By Marshall Hargrave]
The industry gets a little smaller
One risk to Tiffany might be the joining of forces by two of the largest jewelers in the U.S., Signet Jewelers (NYSE: SIG ) and Zale. The acquisition of Zale by Signet will strengthen Signet's market share to 16% for U.S. retail jewelers.
No comments:
Post a Comment